{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:35:15Z","timestamp":1791293715990,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":1467,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.kint.2019.04.024","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T22:28:54Z","timestamp":1557440934000},"page":"906-917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive\u00a0add-on effect in experimental diabetic\u00a0nephropathy"],"prefix":"10.1016","volume":"96","author":[{"given":"Paola","family":"Cassis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Corna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlamaria","family":"Zoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.04.024_bib1","unstructured":"http:\/\/www.idf.org\/diabetesatlas Accessed on March 2016. In (vol 2016)"},{"key":"10.1016\/j.kint.2019.04.024_bib2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMcp011773","article-title":"Clinical practice. Nephropathy in patients with type 2 diabetes","volume":"346","author":"Remuzzi","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.024_bib3","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.024_bib4","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1681\/ASN.2005121324","article-title":"Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study","volume":"17","author":"Remuzzi","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.04.024_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrneph.2014.238","article-title":"Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy","volume":"11","author":"Parving","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2019.04.024_bib6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1681\/ASN.V541139","article-title":"Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started","volume":"5","author":"Perico","year":"1994","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.04.024_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrneph.2010.58","article-title":"The RAAS in the pathogenesis and treatment of diabetic nephropathy","volume":"6","author":"Ruggenenti","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2019.04.024_bib8","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A\u00a0novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2019.04.024_bib9","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A\u00a0human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2019.04.024_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.2162","article-title":"The emerging role of ACE2 in physiology and disease","volume":"212","author":"Hamming","year":"2007","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.kint.2019.04.024_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bph.12159","article-title":"ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis","volume":"169","author":"Simoes e Silva","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.kint.2019.04.024_bib12","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1389450117666160727142401","article-title":"The anti-inflammatory potential of ACE2\/angiotensin-(1-7)\/Mas receptor axis: evidence from basic and clinical research","volume":"18","author":"Rodrigues Prestes","year":"2017","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.kint.2019.04.024_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ki.2014.274","article-title":"Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade","volume":"87","author":"Zhang","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.024_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1042\/CS20140329","article-title":"Angiotensin-(1-7) prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice","volume":"128","author":"Shi","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kint.2019.04.024_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00109-013-1087-0","article-title":"Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats","volume":"92","author":"Santos","year":"2014","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.kint.2019.04.024_bib16","doi-asserted-by":"crossref","first-page":"F812","DOI":"10.1152\/ajprenal.00655.2013","article-title":"Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity","volume":"306","author":"Mori","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.04.024_bib17","article-title":"Angiotensin-(1-7): a novel peptide to treat hypertension and nephropathy in diabetes?","volume":"6","author":"Padda","year":"2015","journal-title":"J\u00a0Diabetes Metab"},{"key":"10.1016\/j.kint.2019.04.024_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/01.HYP.32.3.496","article-title":"Converting enzyme determines plasma clearance of angiotensin-(1-7)","volume":"32","author":"Yamada","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.04.024_bib19","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1021\/jm020108k","article-title":"Synthesis and biological activities of cyclic lanthionine enkephalin analogues: delta-opioid receptor selective ligands","volume":"45","author":"Rew","year":"2002","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.kint.2019.04.024_bib20","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/psc.669","article-title":"The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide","volume":"11","author":"Tugyi","year":"2005","journal-title":"J\u00a0Pept Sci"},{"key":"10.1016\/j.kint.2019.04.024_bib21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/jpet.108.146431","article-title":"Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog","volume":"328","author":"Kluskens","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.kint.2019.04.024_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.peptides.2018.10.015","article-title":"Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models","volume":"112","author":"Kuipers","year":"2019","journal-title":"Peptides"},{"key":"10.1016\/j.kint.2019.04.024_bib23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.peptides.2010.02.015","article-title":"Oral and pulmonary delivery of thioether-bridged angiotensin-(1-7)","volume":"31","author":"de Vries","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.kint.2019.04.024_bib24","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1681\/ASN.2009121290","article-title":"BTBR Ob\/Ob mutant mice model progressive diabetic nephropathy","volume":"21","author":"Hudkins","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.04.024_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000442679","article-title":"Therapy with a selective cannabinoid receptor type 2 agonist limits albuminuria and renal injury in mice with type 2 diabetic nephropathy","volume":"132","author":"Zoja","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2019.04.024_bib26","first-page":"665","article-title":"Nestin structure and predicted function in cellular cytoskeletal organisation","volume":"20","author":"Michalczyk","year":"2005","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.kint.2019.04.024_bib27","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ki.2012.258","article-title":"The glomerular endothelium emerges as a key player in diabetic nephropathy","volume":"82","author":"Satchell","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.024_bib28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3109\/0886022X.2013.773836","article-title":"The renal endothelium in diabetic nephropathy","volume":"35","author":"Eleftheriadis","year":"2013","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2019.04.024_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/molmed.2010.00111","article-title":"Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic\u00a0nephropathy: a comparison with ACE inhibition","volume":"17","author":"Liu","year":"2011","journal-title":"Mol Med"},{"key":"10.1016\/j.kint.2019.04.024_bib30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/ki.2011.381","article-title":"Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy","volume":"81","author":"Batlle","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.024_bib31","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.kint.2016.09.032","article-title":"Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy","volume":"91","author":"Wysocki","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.024_bib32","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.kint.2017.04.001","article-title":"ACE2 as therapy for glomerular disease: the devil is in the detail","volume":"91","author":"Ross","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.024_bib33","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/ki.2012.234","article-title":"Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy","volume":"82","author":"Weil","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.024_bib34","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.2337\/db13-0795","article-title":"Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes","volume":"62","author":"Siddiqi","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2019.04.024_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ki.2012.83","article-title":"Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice","volume":"82","author":"Nadarajah","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.024_bib36","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1681\/ASN.2011121170","article-title":"eNOS deficiency predisposes podocytes to injury in diabetes","volume":"23","author":"Yuen","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.04.024_bib37","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1681\/ASN.2015111219","article-title":"capillary rarefaction associates with albuminuria: the Maastricht study","volume":"27","author":"Martens","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.04.024_bib38","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1681\/ASN.V561378","article-title":"Effects of angiotensin-converting enzyme inhibition on glomerular capillary wall ultrastructure in MWF\/Ztm rats","volume":"5","author":"Iordache","year":"1994","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.04.024_bib39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/TP.0b013e3182241106","article-title":"Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia\/reperfusion in rats","volume":"92","author":"Cassis","year":"2011","journal-title":"Transplantation"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819304867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819304867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:53:23Z","timestamp":1758761603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819304867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0085253819304867"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.04.024","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736688167.793566756","asserted-by":"object"}]},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive\u00a0add-on effect in experimental diabetic\u00a0nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}